36 Healthcare: Stem Cells
Technology Reference No.
Description
STM-0695
Engineering three-dimensional tissue structures using differentiating embryonic stem cells
STM-0721
Growth and differentiation of human embryonic stem cells within three dimensional scaffolds
STM-0722
Stem cell lines derived from delayed blastocyst culture and their uses
STM-0777
L6-IL6 receptor chimera supports the feeder layer-free culture of human embryonic stem cells
STM-0789
Multicellular systems of pluripotent human embryonic stem cells and cancer cells and uses thereof
Human embryonic stem (hES) cells hold promise as an unlimited source of cells for transplantation therapies. The present invention is a method for the control of hES cell proliferation and differentiation into complex, viable 3D tissue constructs. The invention describes the use of biodegradable polymer scaffolds for promoting hES cell growth and differentiation, and for the formation of 3D structures. This approach provides a unique culture system for addressing questions in cell and developmental biology, and provides a potential mechanism for creating viable human tissue structures for therapeutic applications.
The present invention relates to methods for generating embryoid bodies (EB) using three-dimensional scaffolds. The invention describes, for the first time, the generation of EBs on porous scaffolds and demonstrates that hEBs can be generated directly from hES suspensions within 3D porous alginate scaffolds. The scaffold-borne EBs were of a high quality, essentially devoid of necrotic centers, and exhibited a high proliferation rate and differentiation to all three germ layers, while displaying minimal agglomeration. These new methods can be used for isolating multipotent lineage-specific cells and for the largescale production of lineage-specific differentiated cells.
The present invention relates to a method for generating stem cell lines from extended blastocyst cultures (embryos beyond the blastocyst stage). The new technology demonstrates for the first time that multipotent or pluripotent cell lines can be derived from embryos at a later stage than the blastocyst stage. The newly developed method is an opportunity to gain insights into the features of the cells in the post-implantation human embryo – between implantation and gastrulation – using in-vitro models.
Human embryonic stem (hES) cells have contributed significantly to the research on early human development and may have future application in cell-based therapies. These cells have been cultured on mouse embryonic fibroblast (MEF), causing increased risk for exposure to mouse retrovirus. The present invention provides a new feeder layer-free culture system for undifferentiated hES cells for any industrial or clinical uses.
The invention is a novel experimental platform for cancer research that uses human stem cell technology. The process grows human tumor cells in a pre-clinical experimental setting in a tissue micro-environment consisting of differentiated human cells. The multicellular composition is placed in an animal model. The model takes advantage of the potential of human stem cells to differentiate in the experimental setting into any and all of the body’s different cell types, and thus mimics a normal human tissue micro-environment.
Technion - Israel Institute of Technology